Toggle navigation
COVID-19
About
About The ASCO Post
Editorial Board
Rights and Permissions
Contact
Subscribe
News
FDA Update
Journal Spotlight
Expert's Corner
In the Clinic
View By Issue
View All
Meetings
2021 Gastrointestinal Cancers Symposium
2020 San Antonio Breast Cancer Symposium
2020 ASH Annual Meeting & Exposition
ESMO Immuno-Oncology Virtual Congress 2020
ESMO Asia Virtual Congress 2020
Calendar
View All
Topics
Breast Cancer
Lung Cancer
Prostate Cancer
Lymphoma
View All
Videos
Newsreels
Roundtable:
Lymphoma/Myeloma
Roundtable:
Lung Cancer
Podcasts
CME
Methotrexate–Induced Kidney Injury
Advertisement
The ASCO Post Newsreels help clinicians stay up to date on news in the world of clinical oncology and hematology. Newsreels feature leading authorities presenting high-impact clinical findings at major oncology meetings throughout the year.
Showing All Recent Newsreels Videos
Select Meeting
Toggle Dropdown
2021 Gastrointestinal Cancers Symposium
2020 San Antonio Breast Cancer Symposium
2020 ASH Annual Meeting & Exposition
2020 ASTRO Annual Meeting
ESMO Virtual Congress 2020
View all
Advertisement
2021 Gastrointestinal Cancers Symposium
Zev A. Wainberg, MD, on Gastric/Gastroesophageal Junction Adenocarcinoma: Bemarituzumab and FOLFOX
Wasat Mansoor, MBChB, PhD, on Esophageal Cancer: Quality of Life With Pembrolizumab and Chemotherapy
Afsaneh Barzi, MD, PhD, on Disparities in Access to Screening and Treatment of GI Cancers
Rutika Mehta, MD, MPH, on Gastric Cancer: Adjuvant Chemotherapy With S-1 and Docetaxel
Romain Cohen, MD, PhD, on Colon Cancer: Prognostic Value of Tumor Deposits
Kai-Keen Shiu, MD, PhD, on Colorectal Cancer: Pembrolizumab vs Chemotherapy for Microsatellite Instability–High Disease
Milind M. Javle, MD, on Cholangiocarcinoma: Treatment With Infigratinib
Tenna V. Henriksen, PhD Candidate, on Colorectal Cancer: Circulating Tumor DNA Analysis to Improve Treatment
Richard S. Finn, MD, on HCC: Atezolizumab Plus Bevacizumab vs Sorafenib
Talia Golan, MD, on Pancreatic Cancer: Olaparib for BRCA-Mutated Disease
Matthew H.G. Katz, MD, on Pancreatic Cancer: Preoperative mFOLFIRINOX for Resectable Disease
Andrew X. Zhu, MD, PhD, on IDH1-Mutant Cholangiocarcinoma: Ivosidenib vs Placebo
Thierry André, MD, on Mismatch Repair–Deficient Solid Cancers: Safety and Efficacy of Dostarlimab
Rocio Garcia-Carbonero, MD, on Treating Neuroendocrine Tumors of Nonpancreatic Origin With Octreotide Acetate and Axitinib
2020 San Antonio Breast Cancer Symposium
Chirag Shah, MD, on Assessing DCIS Recurrence Risk
Debra A. Pratt, MD, on Time to Completion of Breast Cancer Treatment and Survival
Nadia Harbeck, MD, on Early Breast Cancer: Endocrine Therapy After Preoperative Treatment
Joseph A. Sparano, MD, on HR+, HER2– Breast Cancer: Individualizing Prognosis and Predicting Treatment Success
Patricia A. Ganz, MD, on Younger Breast Cancer Survivors: Managing Depression
Sara A. Hurvitz, MD, on Triple-Negative Breast Cancer: Sacituzumab Govitecan and Chemotherapy
Lee S. Schwartzberg, MD, on HER2– HR+ Breast Cancer: Tesetaxel and Capecitabine
Roisin M. Connolly, MD, on HR+ Advanced Breast Cancer: Endocrine Therapy and Entinostat
Joyce V. Lee, PhD, on Triple-Negative Breast Cancer: MYC as a Predictor of Treatment Response
Sibylle Loibl, MD, on HR+ HER2– Primary Breast Cancer: Palbociclib and Endocrine Therapy
Elizabeth A. Mittendorf, MD, PhD, on Her Plenary Lecture: Local Regional Management Following Neoadjuvant Therapy
Ann H. Partridge, MD, MPH, on ER+, HER2– Breast Cancer: More Effective Treatments Needed
2020 ASH Annual Meeting & Exposition
Ann-Kathrin Eisfeld, MD, on AML in Black Patients: Racial Disparities in Survival Outcomes
Corey Cutler, MD, MPH, on MDS: Evaluating Treatments in Older Patients With Advanced Disease
Emmanuel Bachy, MD, PhD, on Peripheral T-Cell Lymphoma: Romidepsin Plus CHOP
Radhika Gangaraju, MD, and Smita Bhatia, MD, MPH, on Coronary Heart Disease Risk in Blood or Marrow Transplant Survivors
Curtis Lachowiez, MD, on AML: Venetoclax in Combination With Standard Intensive Induction/Consolidation Therapy
Sagar Lonial, MD, on CAR T-Cell Therapies for Myeloma: Novel Approaches and Longer-Term Follow-up Data
Jyoti Nangalia, MBBChir, on MPN: A New Paradigm for the Development of Blood Cancer?
David T. Teachey, MD, on Pediatric Leukemia and Lymphoma: New Findings on Cranial Radiation and Bortezomib
Paul G. Richardson, MD, on Multiple Myeloma: Roundup of Three Key Studies
Matthew S. Davids, MD, on CLL/SLL: New Data on Ibrutinib, Venetoclax, and Rituximab Therapies
Caron A. Jacobson, MD, on Treating Large B-Cell Lymphoma With Axicabtagene Ciloleucel
Ari M. Melnick, MD, on Activated B-Cell–Like DLBCL: Gain-of-Function Mutations and Resistance to Ibrutinib
Meletios A. Dimopoulos, MD, on Multiple Myeloma: Daratumumab, Pomalidomide, and Dexamethasone
Andrew D. Zelenetz, MD, PhD, on Mantle Cell Lymphoma: Immunochemotherapy Plus Lenalidomide
Andrew D. Zelenetz, MD, PhD, on Mantle Cell Lymphoma: Expert Perspective on Key Clinical Trials
Hassan Awada, MD, on AML and Machine Learning: Improving Prognostication
Jorge E. Cortes, MD, on CML: Expert Perspective on Key ASH Abstracts
Farhad Ravandi, MD, on AML: Novel Combination Therapies for Newly Diagnosed Disease
Nitin Jain, MD, on B-Cell ALL: Expert Perspective on Key CAR T-Cell Treatment Advances
Steven M. Horwitz, MD, on T-Cell Lymphoma: Update on Allogeneic Hematopoietic Transplant
Tycel J. Phillips, MD, on Marginal Zone Lymphoma: Efficacy and Safety of Parsaclisib
Steven M. Horwitz, MD, on PTCL: Update on Efficacy of Duvelisib Dose Optimization
Christian Marinaccio, PhD Candidate: Genetic Driver May Play a Role in Progression of Myeloproliferative Neoplasms to AML
Lena E. Winestone, MD, MSHP, on Health-Care Disparities in Hematologic Cancers: Real-World Data
Sara Zarnegar-Lumley, MD, on AML: Prognostic Effects of IDH Mutations
Quantitative Imaging Workshop XVII
Daniel G. Petereit, MD, on Disparities in Lung Cancer Care for Northern Plains American Indians
Fred R. Hirsch, MD, PhD, on Early-Stage Lung Cancer: Targeted Treatment and Screening
David Yankelevitz, MD, on Early-Stage Lung Cancer: Renewed Interest in Combined-Modality Treatment
James L. Mulshine, MD, on Meeting Highlights: Advancing Quantitative Low-Dose CT Imaging in Thoracic Disease
Mary Pasquinelli, DNP, APRN, FNP-BC, on Addressing Lung Cancer Care Equity in Vulnerable Communities
2020 ASTRO Annual Meeting
Neha Vapiwala, MD, on Prostate Cancer: Imaging and the Decision to Treat With Radiation
Arjun Sahgal, MD, on Reducing the Pain of Spinal Metastases: SBRT vs Palliative Radiotherapy
Juliane Hörner-Rieber, MD, on Breast Cancer: Boosting Intensity-Modulated and Conventional Radiotherapies
Paul Sargos, MD, on Prostate Cancer: Adjuvant or Early Salvage Radiotherapy Plus Androgen Deprivation
Youssef Zeidan, MD, PhD, on HER2-Positive Breast Cancer: Deintensifying Radiation Therapy
Cynthia Menard, MD, on Prostate Cancer: PSMA PET- and CT-Guided Intensification of Radiotherapy
Daniel E. Spratt, MD, on Prostate Cancer: Short-Term Adjuvant vs Neoadjuvant Hormone Therapy
Daniel E. Spratt, MD, on Prostate Cancer: Relugolix vs Leuprolide
Alphonse G. Taghian, MD, PhD, on Irradiation for Breast Cancer: Defining the Optimal Dose
Vinai Gondi, MD, on Glioblastoma: Dose Intensification, IMRT, Standard Radiotherapy, and Temozolomide
Jing Li, MD, PhD, on Brain Metastases: Stereotactic Radiosurgery vs Whole-Brain Radiation Therapy
Justin Oh, MD, on Prostate Cancer: Brachytherapy vs External-Beam Radiation Therapy
Jeff M. Michalski, MD, MBA, on Medulloblastoma and Radiation Treatment in Pediatric Patients
2020 ASCO Quality Care Symposium
Melissa K. Accordino, MD, on Breast Cancer Care Delivery: Impact of the COVID-19 Pandemic
Veena Shankaran, MD, on Colorectal Cancer: Cumulative Financial Hardship of Treatment
Joseph M. Unger, PhD, on Patient Interest in Clinical Trial Enrollment: A New Analysis
Katherine Enright, MD, MPH, on Improving the Quality of Oral Cancer Drug Delivery
Marie A. Flannery, PhD, and Eva Culakova, PhD, on Managing Symptoms in Older Adults With Advanced Cancer
Anne M. Barry-Weers, RN, on Decreasing Hospitalizations for Patients Receiving IV Chemotherapy
Cardinale B. Smith, MD, PhD, on Telehealth Disparities During the COVID-19 Pandemic
Cardinale B. Smith, MD, PhD, on Redesigning Care Coordination From the Patient’s Perspective
James D. Murphy, MD, on Opioid Use Among Patients With Cancer
ESMO Virtual Congress 2020
Masahiro Tsuboi, MD, on NSCLC: Adjuvant Osimertinib in EGFR-Mutated Disease
Toni K. Choueiri, MD, on RCC: Nivolumab Plus Cabozantinib vs Sunitinib in First-Line Treatment
Mansoor Raza Mirza, MD, on Endometrial Cancer: Palbociclib Plus Letrozole in ER-Positive Disease
Andreas Schneeweiss, MD, on Breast Cancer: Comparing Neoadjuvant Chemotherapy With Paclitaxel, Doxorubicin, and Carboplatin
Erika P. Hamilton, MD, on Breast Cancer: Abemaciclib With or Without Tamoxifen in HR-Positive, HER2-Negative Metastatic Disease
Ezra E.W. Cohen, MD, on Head and Neck Cancer: Avelumab and Chemoradiotherapy in Locally Advanced Disease
David S. Hong, MD, on NSCLC: Durability of Clinical Benefit and Biomarkers in Patients Treated With Sotorasib
Sumanta K. Pal, MD, on Renal Cell Carcinoma: Cabozantinib Plus Atezolizumab as First-Line Therapy
Nicholas D. James, PhD, MBBS, on Prostate Cancer: Abiraterone Acetate Plus Prednisolone for Hormone-Naive Disease
Stephen R.D. Johnston, MD, PhD, on Early Breast Cancer: Abemaciclib in High-Risk Disease
Thierry Andre, MD, on Colorectal Cancer: Health-Related Quality of Life With Pembrolizumab vs Chemotherapy
Paolo A. Ascierto, MD, on Melanoma: Sequencing Targeted Treatments and Immunotherapy
Benjamin Besse, MD, PhD, on NSCLC: Neoadjuvant Atezolizumab for Resectable Disease
Cécile Le Pechoux, MD, on NSCLC: Comparing Postoperative Radiotherapy With No Radiotherapy
Erica L. Mayer, MD, MPH, on Early Breast Cancer: Palbociclib With Endocrine Therapy vs Endocrine Therapy Alone
Aditya Bardia, MD, MPH, on Triple-Negative Breast Cancer: Sacituzumab Govitecan vs Treatment of Physician’s Choice
Alexander M. Eggermont, MD, PhD, on Melanoma: Pembrolizumab vs Placebo After Complete Resection
Lisa A. Carey, MD, on Triple-Negative Breast Cancer: Paclitaxel, Nab-paclitaxel, and Atezolizumab in IMpassion Trials
Monika K. Krzyzanowska, MD, MPH, on Early-Stage Breast Cancer: Ambulatory Toxicity Management in the AToM Study
Jeffrey S. Weber, MD, PhD, on Melanoma: Adjuvant Nivolumab vs Ipilimumab
Andreas du Bois, MD, PhD, on Ovarian Cancer: Niraparib, Trabectedin Plus Doxorubicin, Platinum, and Carboplatin
IASLC World Conference on Lung Cancer
Paul Baas, MD, PhD, on Mesothelioma: First-Line Nivolumab Plus Ipilimumab vs Chemotherapy
Misako Nagasaka, MD, on NSCLC: Sintilimab, Pemetrexed, and Platinum as First-Line Therapy
Leora Horn, MD, on NSCLC: Ensartinib vs Crizotinib in ALK–Positive Disease
Marina C. Garassino, MD, on COVID-19 and Thoracic Malignancies: TERAVOLT Registry
ASCO20 Virtual Education Program
Matti S. Aapro, MD, on Curing Sarcomas: An Expert Review
AACR Virtual Meeting: COVID-19 and Cancer
Arthur L. Caplan, PhD, on Ethics, Cancer, and COVID-19
Karen E. Knudsen, MBA, PhD, on the Challenges of Using Telehealth in Cancer Care
Catherine H. Marshall, MD, MPH, on Promoting Recovery From COVID-19 Infection With Endocrine Therapy
Antoni Ribas, MD, PhD, on AACR Virtual Meeting: COVID-19 and Cancer Highlights
Nancy E. Davidson, MD, on Bringing Patients With Cancer Back to the Clinic During the COVID-19 Pandemic
Jessica Y. Islam, PhD, MPH, on COVID-19 Preventive Behaviors Among Cancer Survivors
Gabriella Pravettoni, PhD, on COVID-19 and Cancer: Psychological Effects on Patients and Oncologists
Dafna Bar-Sagi, PhD, on COVID-19: How Cancer Researchers Can Help Address the Challenges
First International Summit on Interventional Pharmacoeconomics
Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States
R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options
Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib
Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges
Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting
Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know
Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care
Welcome and Introduction to Vi3C
Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?
Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How
Opening Session Panel Discussion
Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept
Varsha Gandhi, PhD, on Ibrutinib
Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors
S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma
Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia
Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19
Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority
Gary L. Rosner, ScD, on Bayesian Non-Inferiority
Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?
Clinical Trial Design: Statistical Options/Challenges Panel Discussion
Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics
David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease
Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?
Peter Clark, MA, MD, FRCP: A Payer Perspective
Amit Sanyal, MD: A Clinician’s Perspective
Matthew Seymour, MD: A Clinical Trialist’s Perspective
CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country
Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If
Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective
Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)
Opportunities to Optimize Cancer Policies Panel Discussion
Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone
David A. Hyman, MD, JD, on Inclusive Shared Savings
R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies
Deborah Collyar: What's In It for Patients?
The Interventional Pharmacoeconomic Toolbox Panel Discussion
Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors
Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib
Focus on Optimized Dosing of Ibrutinib Panel Discussion
Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics
AACR Virtual Annual Meeting 2020 II
Nasser K. Altorki, MD, on Lung Cancer: Radiotherapy and Immune Checkpoint Blockade in the Neoadjuvant Setting
Adam C. Palmer, PhD, on Immune Checkpoint Inhibitors: Additive to or Synergistic With Other Treatments?
Stacey A. Fedewa, PhD, on Cancers in Younger Populations: Current Trends
Alfonso Bencomo Álvarez, PhD, on ALL, AML, and CML: Survival for Hispanic Patients Living Near the US/Mexico Border
Antoni Ribas, MD, PhD, on Racism and Racial Inequities in Cancer Research
Xavier Llor, MD, PhD, on Colorectal Cancer: Why Are More Younger People Being Affected?
Silvia Formenti, MD, on Testing Radiation and Immune Checkpoint Blockade in Different Tumor Settings
Ramaswamy Govindan, MD, on Differences Among Male and Female Patients With Lung Cancer
Ralph R. Weichselbaum, MD, on Radiotherapy and Immunotherapy in Oligometastatic Disease
Antoni Ribas, MD, PhD, on Turning Science Into Life-Saving Care
Kala Visvanathan, MD, on Ovarian Cancer: Lowering Mortality With Lipophilic Statins
Robert A. Winn, MD, on the Impact of COVID-19 on Cancer Care Among Racial and Ethnic Minorities
Elizabeth H. Stover, MD, PhD, on Ovarian Cancer: Nivolumab Plus Bevacizumab for Relapsed Disease
EHA25 Virtual
Abhishek Maiti, MBBS, on AML: Decitabine and Venetoclax vs Intensive Chemotherapy
Courtney D. DiNardo, MD, on AML: Venetoclax and Azacitidine for Treatment-Naive Patients
Anthony Moorman, PhD, on ALL: Improving Outcomes With a Tyrosine Kinase Inhibitor Plus Chemotherapy
Michael J. Dickinson, MBBS, DMedSc, on Non-Hodgkin Lymphoma: Early Study Findings With Novel T-Cell–Engaging Bispecific Antibody
Elias Jabbour, MD, on Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma: Venetoclax and Navitoclax in Relapsed or Refractory Disease
John C. Byrd, MD, on CLL/SLL: Acalabrutinib in Treatment-Naive Patients
Elizabeth H. Phillips, MD, on DLBCL: Inotuzumab Ozogamicin Plus Chemotherapy in Front-Line Setting
Efstathios Kastritis, MD, on Amyloidosis: Daratumumab Plus Cyclophosphamide, Bortezomib, and Dexamethasone
Jorge E. Cortes, MD, on Chronic Phase CML: Comparing Three Starting Doses of Ponatinib
Arnon P. Kater, MD, PhD, on CLL: Efficacy of Venetoclax in Relapsed or Refractory Disease
Andrew H. Wei, MBBS, PhD, on AML: Venetoclax Plus Cytarabine in Older Patients
ASCO20 Virtual Scientific Program
Welcome to This Year’s Meeting: A Message From ASCO President Howard A. Burris III, MD, FACP, FASCO
David C. Fajgenbaum, MD, MBA, on Chasing His Cure: A Physician Is Battling His Disease and Beating the Odds
Richard L. Schilsky, MD, on This Year’s Practice-Changing Findings
Roy S. Herbst, MD, PhD, on NSCLC: Osimertinib in Stage IB–IIIA EGFR Mutation–Positive Disease
Christopher Sweeney, MBBS, and Thomas Powles, MD, PhD, on Urothelial Cancer: The JAVELIN Bladder 100 Study on Avelumab vs Best Supportive Care
Seema A. Khan, MD, MPH, on Metastatic Breast Cancer: Systemic vs Locoregional Therapies
Shaji Kumar, MD, on Multiple Myeloma: Phase III Results on Carfilzomib, Lenalidomide, Bortezomib, and Dexamethasone
Thierry André, MD, on Colorectal Cancer: Pembrolizumab vs Chemotherapy for Metastatic Disease
Andres Poveda, MD, on Ovarian Cancer: Assessing Maintenance Olaparib
Leora Horn, MD, on Thoracic Cancer and COVID-19: How Type of Cancer Therapy May Affect Survival
Merry-Jennifer Markham, MD: Perspectives on Three Abstracts From the ASCO Cancer Communications Chair
Metastatic Urothelial Cancer: A Conversation on State-of-the-Art Treatment Before the ASCO20 Virtual Scientific Program
Howard A. Burris III, MD, FACP, FASCO, on Highlights of the ASCO20 Virtual Scientific Program
Nancy U. Lin, MD, on Metastatic Breast Cancer: Tucatinib, Trastuzumab, and Capecitabine
Scott Kopetz, MD, PhD, on Colorectal Cancer: Encorafenib Plus Cetuximab With or Without Binimetinib
Fatima Cardoso, MD, on Breast Cancer: MammaPrint as Guidance for Adjuvant Chemotherapy
Jeffrey A. Meyerhardt, MD, MPH, on Colon Cancer: Celecoxib and FOLFOX for Stage III Disease
Michael S. Hofman, MBBS, on Prostate Cancer: LuPSMA vs Cabazitaxel in Metastatic Castration-Resistant Disease
David R. Wise, MD, PhD, on Novel Biomarkers in Prostate Cancer: Is Tissue the Issue?
Rana R. McKay, MD, on Prostate Cancer: Intense Androgen-Deprivation Therapy Before Radical Prostatectomy
Alberto F. Sobrero, MD, on Colon Cancer: Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy for Stage III Disease
Neal D. Shore, MD, on Prostate Cancer: Relugolix vs Leuprolide for Advanced Disease
Cynthia X. Ma, MD, PhD, on Breast Cancer: Neoadjuvant Endocrine Treatment for ER-Positive, HER2-Negative Disease
Eric Jonasch, MD, on a Novel Therapy for Von Hippel-Lindau Disease–Associated RCC
Meletios A. Dimopoulos, MD, on Multiple Myeloma: Selinexor, Bortezomib, and Dexamethasone for Previously Treated Patients
Sara A. Hurvitz, MD, on Breast Cancer: Four Major Studies on Trastuzumab, Pertuzumab, Anthracyclines, and Chemotherapy De-escalation
Michael J. Morris, MD, on Prostate Cancer: Impact of PSMA-Targeted Imaging on Clinical Management
Tingyan Shi, MD, PhD, on Ovarian Cancer: Secondary Cytoreductive Surgery for Recurrent Disease
Daniel P. Petrylak, MD, on Prostate Cancer: First-in-Human Study of ARV-110 Shows Antitumor Activity
Ursula A. Matulonis, MD, on Ovarian Cancer: Roundup of Studies on Olaparib, Cediranib, Mirvetuximab Soravtansine, Bevacizumab, and Pembrolizumab
Lourdes Gil Deza on Caring for Transgender Patients With Cancer
Mikkael A. Sekeres, MD, on MDS, CMML, or AML: Pevonedistat and Azacitidine
Farhad Ravandi-Kashani, MD, on Acute Myeloid Leukemia: AMG 330 in Patients With Relapsed or Refractory Disease
Reshma Jagsi, MD, DPhil, and Narjust Duma, MD, on Diversity in Oncology: A Discussion of Evidence-Based Transformation
Jeremy L. Warner, MD, on the Clinical Impact of COVID-19 on Patients With Cancer
Douglas B. Johnson, MD, on Melanoma: Clinical Trials Update on PD-1 and CTLA-4 Blockade
Christopher Nutting, MD, PhD, on Head and Neck Cancer: Dysphagia-Optimized vs Standard IMRT
Rachel E. Sanborn, MD, on NSCLC: Maximizing the Benefits of Targeted Therapies for EGFR-Mutated Disease
Nirav Niranjan Shah, MD, on DLBCL: Autologous Transplant vs CAR T-Cell Therapy
Suresh S. Ramalingam, MD, on NSCLC: Nivolumab Plus Ipilimumab vs Chemotherapy
Lakshmi Nayak, MD, on Primary CNS Lymphoma: The Search for Optimal First-Line Treatment
Egbert F. Smit, MD, PhD, on NSCLC: Treatment With Fam-trastuzumab Deruxtecan
Peter Reichardt, MD, PhD, on GIST: Adjuvant Imatinib for High-Risk Disease
Parameswaran Hari, MD, on Multiple Myeloma: Post-Autologous Hematopoietic Cell Transplantation Strategies in Upfront Treatment
Nikhil C. Munshi, MD, on Multiple Myeloma: Idecabtagene Vicleucel in Patients With Relapsed or Refractory Disease
Patricia Pautier, MD, on Leiomyosarcoma: Doxorubicin and Trabectedin for First-Line Treatment
Paul G. Richardson, MD, on Multiple Myeloma: First-in-Human Study of the Novel Agent CC-92480
Parameswaran Hari, MD, on Multiple Myeloma: Expert Commentary on Four Key Abstracts
Sarah A. Holstein, MD, PhD, on Multiple Myeloma: Expert Perspective on Five Key ASCO20 Abstracts
Howard A. Burris III, MD, FACP, FASCO, on the ASCO20 Virtual Scientific Program: After Action Report
Eric Zhou, PhD, on Insomnia in Young Cancer Survivors: Online Program May Improve Quality of Life
AACR Virtual Annual Meeting 2020 I
Lajos Pusztai, MD, PhD, on Breast Cancer: I-SPY2 Trial on Durvalumab, Olaparib, and Paclitaxel
Steven J. O’Day, MD, on Triple-Negative Breast Cancer: Clinical Benefit With Pembrolizumab Plus Imprime PGG
Grant A. McArthur, MBBS, PhD, on Melanoma: IMspire150 Trial of Atezolizumab, Cobimetinib, and Vemurafenib
Ryan J. Sullivan, MD, on Advanced Solid Tumors: Antitumor Activity With COM701 Plus Nivolumab
Kimlin T. Ashing, PhD, on Tobacco and Vape Shops in Neighborhoods With Lower-Income and Minority Populations
Byoung Chul Cho, MD, PhD, on NSCLC: Genetic Mutations and Immunotherapy vs Chemotherapy in KEYNOTE-042
Nickolas Papadopoulos, PhD, on Liquid Biopsy to Screen for Multiple Cancer Types
Edward B. Garon, MD, on NSCLC: Long-Term Use of Pemetrexed Plus Platinum With Pembrolizumab
Edward B. Garon, MD, on Metastatic NSCLC: GEOMETRY mono-1 Trial of Capmatinib
Jennifer K. Litton, MD, on Breast Cancer: EMBRACA Trial on Talazoparib vs Chemotherapy
Qi Liu, PhD, on NSCLC: Pneumonitis, Immunotherapy, and Chemotherapy
Andrew X. Zhu, MD, PhD, on Hepatocellular Carcinoma: Atezolizumab Combined With Bevacizumab
NCCN 2020 Virtual Annual Conference
Elizabeth Reed, MD, on Helping Providers in Rural Areas Meet the Needs of Younger Patients With Breast Cancer
William J. Gradishar, MD, on Innovating Pathways for Patient Self-Management in Breast Cancer
Karen Wonders, PhD, on Benefits of Exercise During Cancer Treatment
Apar Kishor Ganti, MD, on NSCLC: Real-World Adherence and Persistence of ALK Inhibitors
Sara A. Hurvitz, MD, on Talazoparib vs Chemotherapy for Breast Cancer: Results From the EMBRACA Trial
Hope S. Rugo, MD, on Talazoparib for Advanced Solid Tumors: Reduced Hospitalization and Supportive Care
Barbara DeVivo, PhD, MBA, on Tumor Boards: The Influence of Social Hierarchy on Cancer Treatment Decision-Making
Pam Baker DeGuzman, PhD, on Assessing Distress During Telemedicine Visits With Rural Survivors of Head and Neck Cancer
Christopher D'Avella, MD, on Utilizing a Specialized Urgent Care Center for Patients With Cancer
COVID-19 and Cancer Care
Miguel-Angel Perales, MD, and Syed A. Abutalib, MD, on Bone Marrow Transplants During the COVID-19 Pandemic
Mikkael A. Sekeres, MD, on Cancer Treatment in the Age of COVID-19: Personal Observations
William Dale, MD, PhD, on Best Practices for Special Populations During the COVID-19 Pandemic
Laura C. Michaelis, MD: In My Experience Question 1
Laura C. Michaelis, MD: In My Experience Question 2
Laura C. Michaelis, MD: In My Experience Question 3
Laura C. Michaelis, MD: In My Experience Question 4
Laura C. Michaelis, MD: In My Experience Question 5
Mehdi Hamadani, MD: In My Experience Question 1
Mehdi Hamadani, MD: In My Experience Question 2
Mehdi Hamadani, MD: In My Experience Question 3
Mehdi Hamadani, MD: In My Experience Question 4
Mehdi Hamadani, MD: In My Experience Question 5
Mehdi Hamadani, MD: In My Experience Question 6
Saad Z. Usmani, MD: In My Experience Question 1
Saad Z. Usmani, MD: In My Experience Question 2
Saad Z. Usmani, MD: In My Experience Question 3
Saad Z. Usmani, MD: In My Experience Question 4
Saad Z. Usmani, MD: In My Experience Question 5
Rafal Dziadziuszko, MD, PhD, on Using Telemedicine During the Pandemic: Experience in Poland
Rafal Dziadziuszko, MD, PhD, on Helping Ease Oncology Patients’ Fears of Contracting COVID-19
Jacek Jassem, MD, PhD, on Fighting COVID-19 and Cancer: The View From Poland
Paolo A. Ascierto, MD, on Cancer Treatment During the COVID-19 Pandemic: The View From Southern Italy
Joseph C. Alvarnas, MD, on the Increased Risk of Side Effects for Patients With Cancer and COVID-19
Giorgio V. Scagliotti, MD, PhD, on the Oncoming Waves of COVID-19: Italy’s Experience
Giorgio V. Scagliotti, MD, PhD, on the Ongoing Battle Against COVID-19: Update From Italy
Eduardo L. Cazap, MD, PhD, on COVID-19: The View From South America
Derek Raghavan, MD, PhD, on COVID-19 and Cancer Care: The View From North Carolina
Nancy E. Davidson, MD, on COVID-19 and Cancer Care: Thoughts From the Seattle Epicenter
William A. Wood, MD, MPH, on the New ASH Research Collaborative Data Hub COVID-19 Registry for Hematologic Malignancy
Irene M. Ghobrial, MD, on How COVID-19 is Changing the Conduct of Clinical Trials
Giuseppe Curigliano, MD, PhD, on How COVID-19 Is Affecting Cancer Care: The View From Italy
Karen E. Knudsen, PhD, MBA, on Delivering Cancer Care During the COVID-19 Pandemic: Report From Philadelphia
2020 Multidisciplinary Head and Neck Cancers Symposium
Francis P. Worden, MD, on the Role of Induction Chemotherapy in Laryngeal Preservation
Carryn M. Anderson, MD, on Reducing Severe Oral Mucositis and Its Effect on Patient Outcomes
Nadeem Riaz, MD, on Established and Emerging Biomarkers for Immunotherapy in Head and Neck Cancer
Assuntina G. Sacco, MD, on Head and Neck Squamous Cell Carcinoma: Trial Results on Pembrolizumab and Cetuximab
Jill Gilbert, MD, on HPV-Associated Oropharyngeal Cancer: Challenges in De-intensifying Systemic Therapies
David Adelstein, MD, on Guidelines for Treating HPV-Associated Oropharyngeal Squamous Cell Carcinoma
Gopal K. Bajaj, MD, MBA, on Reducing Opioid Use in Patients With Head and Neck Cancer Undergoing Radiotherapy
Jonathan D. Schoenfeld, MD, MPH, on Oral Cavity Cancer: Neoadjuvant Nivolumab With or Without Ipilimumab
Jared Weiss, MD, on Squamous Cell Carcinoma of the Head and Neck: When Standard Therapy is Contraindicated
Sue Sun Yom, MD, PhD, on HPV-Associated Oropharyngeal Cancer: Challenges in De-intensifying Radiation Therapy
2020 Genitourinary Cancers Symposium
Jonathan E. Rosenberg, MD, on Locally Advanced or Metastatic Urothelial Carcinoma: Enfortumab Vedotin Plus Pembrolizumab
Syed A. Hussain, MD, on Muscle-Invasive Bladder Cancer: NEO-BLADE Trial of Nintedanib Plus Chemotherapy
David P. Dearnaley, MD, on Prostate Cancer: Conventional vs Hypofractionated High-Dose Radiotherapy
Julie N. Graff, MD, on Castration-Resistant Prostate Cancer: Results From KEYNOTE-199 on Pembrolizumab Plus Enzalutamide
Ziad Bakouny, MD, on Metastatic Kidney Cancer: Defining the Role of Cytoreductive Nephrectomy
Toni K. Choueiri, MD, on an HIF2A Inhibitor for Advanced Clear Cell RCC
Neeraj Agarwal, MD, on Castration-Resistant Prostate Cancer: Results From the COSMIC-021 Study of Cabozantinib and Atezolizumab
Maha Hussain, MD, on Next-Generation Sequencing of Prostate Tumor Tissue: Results From the PROfound Study
Nicholas D. James, PhD, MBBS, on Bladder Cancer: Cetuximab With Chemoradiotherapy
Karim Fizazi, MD, PhD, on Prostate Cancer: Pain and Quality of Life in Patients Receiving Cabazitaxel vs Abiraterone or Enzalutamide
Thomas Powles, MD, PhD, on Adding Radiation to Immunotherapy for RCC: Improving Systemic Control Through Local Therapy
Nizar M. Tannir, MD, on Nivolumab/Ipilimumab vs Sunitinib in Advanced Kidney Cancer
Hannah L. Rush, MBChB, on Prostate Cancer: Comparing Quality of Life in Patients Receiving Docetaxel or Abiraterone
Toni K. Choueiri, MD, on COSMIC-313: Cabozantinib in Combination With Nivolumab/Ipilimumab in RCC
Ziad Bakouny, MD, on Sarcomatoid and Rhabdoid RCC: Potential Determinants of Poor Prognosis and Treatment Response
Nicholas D. James, PhD, MBBS, on Adding Abiraterone to Hormone Therapy in Prostate Cancer: STAMPEDE Trial on Cost-Effectiveness
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
Elizabeth A. Mittendorf, MD, PhD, on Mobilizing the Immune System to Treat Select Solid Tumors
Dario Vignali, PhD, on Immune Resistance Mechanisms in Cancer
Luis I. Ruffolo, MD, on Pancreatic Cancer: Augmenting Immunotherapy With Antibody Blockade of Semaphorin 4D
Philippa G. Corrie, PhD, on Patient Outcomes in Melanoma After Immune Checkpoint Inhibition
Martin McCarter, MD, on Refinement of Surgical Treatment: Expert Perspective on ASCO’s 2020 Advance of the Year
Jacob J. Adashek, DO, on Immunoregulatory Molecules, Cancer Genes, and Therapeutic Insights
Kevin Tyan on Colitis Induced by Immune Checkpoint Inhibitors: Potential Preventive Strategy
Christopher B. Cole, MD, PhD, on Ovarian Cancer: First-in-Human Study of Interferon-Activated Autologous Monocytes
John N. Lukens, MD, on Advanced Melanoma: Antibiotics, Survival, and Colitis in Patients Receiving Immunotherapy
Jarrett Failing, MD, on Human Leukocyte Antigen Expression in NSCLC With Brain Metastases
Advertisement
Advertisement
Jan
23
Today In Oncology
New Study Finds Suspicious Lesions on Breast MRI in Neoadjuvant Setting Are Unlikely to Be Malignant
IMpower133 Update Atezolizumab Plus Carboplatin/Etoposide for Extensive-Stage Small Cell Lung Cancer
Belantamab Mafodotin-blmf in Multiple Myeloma Number of Prior Treatments No Hindrance to Efficacy
Multiancestry Meta-analysis of Prostate Cancer Genetics
Final Overall Survival Results of the IDEA Collaboration 3 vs 6 Months of Adjuvant Chemotherapy for Stage III Colon Cancer
View More
Advertisement